Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT

Published:2021-08-25 Issue:5 Volume:8 Page:3875-3884
ISSN:2055-5822
Container-title:ESC Heart Failure
language:en
Short-container-title:ESC Heart Failure

Author:

Nativi‐Nicolau Jose¹,Judge Daniel P.²,Hoffman James E.³,Gundapaneni Balarama⁴,Keohane Denis⁵,Sultan Marla B.⁵,Grogan Martha⁶

Affiliation:

1. Department of Medicine University of Utah Health Care Salt Lake City UT USA

2. Medical University of South Carolina Charleston SC USA

3. University of Miami Miami FL USA

4. Pfizer Inc Groton CT USA

5. Pfizer Inc New York NY USA

6. Department of Cardiovascular Diseases Mayo Clinic Rochester MN USA

Funder

Pfizer

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ehf2.13541

Reference24 articles.

1. Transthyretin (TTR) Cardiac Amyloidosis

2. Transthyretin-related amyloidoses and the heart: a clinical overview

3. Transthyretin Amyloid Cardiomyopathy

4. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction

5. Left Ventricular Amyloid Deposition in Patients With Heart Failure and Preserved Ejection Fraction

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes in Cardiac Transthyretin Amyloidosis and Association With New York Heart Association Class: Real‐World Data;Journal of the American Heart Association;2024-07-16

2. Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review;Journal of Comparative Effectiveness Research;2024-07

3. Long‐term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction;European Journal of Heart Failure;2024-06-26

4. Advancing Transthyretin Amyloidosis Drug Development in an Evolving Treatment Landscape: Amyloidosis Forum Meeting Proceedings;Advances in Therapy;2024-06-04

5. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan;ESC Heart Failure;2024-05-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3